

German Title: MAHOGANY: eine Phase-3-Studie mit Zanubrutinib plus Anti-CD20-Antikörper versus Lenalidomid plus Rituximab bei Patienten mit rezidivierenden oder refraktären folliculären Lymphomen oder Marginalzonen-Lymphomen

English Title: MAHOGANY: A Phase 3 Trial of Zanubrutinib (ZANU) Plus Anti-CD20 Antibodies vs Lenalidomide Plus Rituximab (L+R) in Patients (pts) With Relapsed or Refractory (R/R) Follicular or Marginal Zone Lymphoma (FL or MZL)

Authors: Christian Buske¹, Loretta J. Nastoupil², Yuqin Song³, Laurie Sehn⁴, Clémentine Sarkozy⁵, Pier Luigi Zinzani⁶, Antonio Salar⁷, Jun Zhang⁸, Wanhua Zhang⁸, Pierre Fustier⁹, Richard Delarue⁹, Judith Trotman¹⁰

Institution: ¹Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm, University Hospital Ulm, Ulm, Germany; ²MD Anderson Cancer Center, Houston, TX, USA; ³Peking University Cancer Hospital and Institute, Beijing, China; ⁴University of British Columbia, Vancouver, BC, Canada; ⁵Institut Curie, Saint Cloud, Paris, France; ⁶University of Bologna, Bologna, Italy; ⁷Hospital del Mar, Barcelona, Spain; ⁸BeiGene (Shanghai) Co., Ltd. Shanghai, China; BeiGene USA, Inc., San Mateo, CA, USA; ⁹BeiGene Switzerland GmbH, Basel, Switzerland; ¹⁰Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

Introduction: Bruton tyrosine kinase inhibitors (BTKis) have emerged as a treatment strategy for pts with B-cell malignancies, including indolent non-Hodgkin lymphomas. ZANU, a potent and specific second-generation BTKi, has demonstrated improved efficacy and tolerability over first-generation BTKis in several diseases, including chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenström macroglobulinemia. ZANU is approved in >15 countries, including the US and countries in the EU, for pts with R/R MZL who received ≥1 anti-CD20–based regimen, based on the single-arm MAGNOLIA trial (Opat et al. *Clin Cancer Res.* 2021;27[23]:6323-32). In ROSEWOOD, a phase 2 randomized study in R/R FL, ZANU plus obinutuzumab (Z+O) demonstrated an increased overall response rate (ORR) vs obinutuzumab alone and had a favorable safety profile (Zinzani et al. *J Clin Oncol.* 2022;40[suppl 16]:7510).

Trial design: MAHOGANY (BGB-3111-308; NCT05100862), a randomized, open-label phase 3 trial, will compare the efficacy and safety of ZANU plus an anti-CD20 monoclonal antibody vs L+R in 2 independent cohorts of pts with R/R FL or MZL. Key eligibility criteria include histologically confirmed FL (grades 1-3A) or MZL, ≥1 prior anti-CD20–based regimen, disease that relapsed after or is refractory to the most recent systemic therapy, need for treatment, naivety to BTKi treatment, and no prior resistance to a lenalidomide-based regimen. In the FL cohort, 600 pts will be randomized 1:1 to Z+O or L+R. In the MZL cohort, 150 pts will be randomized 1:1 to ZANU plus rituximab or L+R. Randomization for both cohorts is stratified by age (≥60 vs <60 years) and number of prior lines of therapy (1-2 vs >2), with the FL cohort also stratified by rituximab-refractory status (yes vs no). The primary endpoint in both cohorts is progression-free survival as assessed by an independent review committee (IRC), according to Lugano 2014 criteria. Key secondary endpoints are ORR by IRC assessment (both cohorts) and overall survival (FL cohort). ZANU is given at 160 mg twice daily or 320 mg once daily, according to investigator, until progression or unacceptable toxicity. Obinutuzumab or rituximab is given for up to 8 infusions. Lenalidomide is given following the approved label for up to 12 cycles. Recruitment is ongoing.